Capture Bead Assay for SARS-CoV-2 Antibody Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current SARS-CoV-2 serological tests typically only measure antibodies against a single viral protein, leading to concerns about specificity and sensitivity, and lack the ability to assess vaccine effectiveness by comparing immune responses to natural infection and vaccination.
Innovation Solution
A composition and method using capture beads conjugated with multiple SARS-CoV-2 antigens, including spike, nucleocapsid, envelope, and hemagglutinin-esterase dimer proteins, for detection by flow cytometry, allowing for the measurement of antibodies in a patient sample to improve specificity and sensitivity and evaluate vaccine effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current SARS-CoV-2 serological tests measure only a single viral protein, then the test structure is simple and easy to manufacture, but the specificity and sensitivity are insufficient
Solution Approach 1:
The test system is segmented into multiple independent capture beads, each conjugated to a different SARS-CoV-2 antigen (spike, nucleocapsid, envelope, hemagglutinin-esterase dimer proteins). This segmentation allows simultaneous detection of multiple antibodies in parallel, improving measurement precision while maintaining manageable complexity through modular design
Solution Approach 2:
The test system achieves multi-functionality by incorporating multiple antigens on capture beads that can detect various antibody types (IgM, IgG, IgA) against different viral proteins simultaneously. This universal approach enables comprehensive immune response assessment in a single test, enhancing both specificity and sensitivity
2Reliability
If multiple antigens are measured simultaneously, then the accuracy and reliability improve, but the device complexity and manufacturing difficulty increase
Solution Approach 1:
The system uses parameter changes by varying the antigen types conjugated to different capture beads (spike, nucleocapsid, envelope, hemagglutinin-esterase dimer proteins) while maintaining consistent bead characteristics. This allows reliable multi-antigen detection through controlled variation of antigen parameters rather than fundamentally changing the entire system architecture
Solution Approach 2:
The patent employs copying by creating multiple identical capture beads, each coated with a specific antigen. These replicated beads are then combined in defined ratios to achieve multi-antigen detection. This copying approach simplifies manufacturing by allowing standardized bead production followed by controlled mixing, rather than requiring complex multi-component assembly
3Adaptability or versatility
If a single antigen is tested, then the test is rapid and simple to operate, but it cannot differentiate between immune responses from natural infection and vaccination
Solution Approach 1:
The test system adds another dimension to antigen detection by incorporating multiple antigen types (spike, nucleocapsid, envelope, hemagglutinin-esterase dimer) that target different aspects of the immune response. This dimensional expansion enables differentiation between infection and vaccination responses while maintaining operational simplicity through automated flow cytometry analysis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the accuracy and reliability of SARS-CoV-2 testing by measuring multiple antigens, providing improved specificity and sensitivity, and enabling the differentiation of immune responses from natural infection and vaccination.
Implementation Method 1
A composition and method using capture beads conjugated with multiple SARS-CoV-2 antigens, including spike, nucleocapsid, envelope, and hemagglutinin-esterase dimer proteins, for detection by flow cytometry, allowing for the measurement of antibodies in a patient sample
Data Source
AI summary
Described herein are compositions for detecting an antigen, including but not limited to, a SARS-CoV-2 antigen, in a sample using a flow cytometry platform. The use of the flow cytometry platform described herein allows for the detection of one or more antibodies in a sample from a patient.